| Objective: To observe the efficacy of tegafur combined with apatinib in the treatment of advanced recurrent and metastatic esophageal cancer and its effect on T cell subsets and serum tumor marker levels. Methods: The case collection time was from March 2015 to March 2018, and the case collection scope was 70 patients with advanced recurrent and metastatic esophageal cancer in our hospital. The patients were divided into control group and experimental group by envelope lottery, with 35 cases in each group. The control group was treated with tegafur, and the experimental group was treated with apatinib on the basis of the control group.Both groups received chemotherapy for 2 cycles.Objective remission rate and disease control rate at 2 cycles after chemotherapy were compared between the two groups.T cell subsets and serum tumor markers levels before and 2 cycles after chemotherapy were compared between the two groups. Median overall survival (mOS), median progression free survival (mPFS) and quality of life scores were compared between the two groups. The toxicological and side effects during chemotherapy were recorded. Results:The objective remission rate and disease control rate of the experimental group were 45.71% and 68.57% respectively, which were higher than 22.86% and 42.86% of the control group (P<0.05). 2 cycles after chemotherapy, CD3+, CD4+, CD4+/CD8+ of two groups were lower than those before chemotherapy, but the experimental group was higher than the control group (P<0.05). CD8+ was higher than that before chemotherapy, but the experimental group was lower than the control group (P<0.05). 2 cycles after chemotherapy, the levels of tumor specific growth factor (TSGF), carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) of two groups were lower than those before chemotherapy, and the experimental group was lower than the control group (P<0.05). The mOS and mPFS of the experimental group were longer than those of the control group (P<0.05). The QLQ-OES24 score of the two groups at 3 months after chemotherapy increased, and the experimental group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: After treatment of advanced recurrent and metastatic esophageal cancer with tegafur combined with apatinib, the condition is effectively controlled, the serum tumor markers levels are decreased more significantly, the immunosuppression is alleviated, the mOS and mPFS are prolonged, and the side effects are not increased. The short-term curative effects is reliable. |
